Imatinib plus Cetuximab as a Window of Opportunity Clinical Trial in Head and Neck Cancer
J.Y. Bruce,T. Glazer,M. Iida,B. Mehall,K.L. Kostecki,M. Yu,A. Wieland,G.K. Hartig,T.M. McCulloch,D. Trask,A. Burr,P.M. Harari,R.J. Kimple,D.L. Wheeler
DOI: https://doi.org/10.1016/j.ijrobp.2024.01.158
IF: 8.013
2024-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s) Cetuximab, an approved anti-EGFR receptor monoclonal antibody, is used for the treatment of metastatic cancer, often in conjunction with cytotoxic chemotherapy. It is also employed as a radiosensitizer in the context of definitive radiation therapy for locally advanced cases. However, overcoming resistance to cetuximab, whether intrinsic or acquired, represents a significant challenge in clinical practice. In preclinical studies, the identification of tyrosine 821 (Y821) on the C-terminal of AXL has been linked to resistance to both cetuximab and radiation therapy via signaling through the tyrosine kinase c-Abl. Blocking c-Abl signaling with the tyrosine kinase inhibitor imatinib restored sensitivity to cetuximab and radiotherapy, ultimately resulting in complete tumor regression without recurrence in models of head and neck cancer. In this clinical trial, we aim to translate these promising preclinical findings into clinical practice through a window-of-opportunity trial that evaluates the effects of combining cetuximab with imatinib in head and neck cancer patients. Materials/Methods This is a window-of-opportunity study conducted at a single center, involving patients diagnosed with head and neck squamous cell carcinoma who are undergoing treatment with surgery, radiation, or chemoradiation. A total of 15 patients will be recruited for this study. Participants will initially undergo a medical history review and physical examination and provide written informed consent. To be eligible, subjects must have sufficient tumor volume to allow for a minimum of two core research biopsies. The first research biopsy will be performed at baseline prior to therapy to analyze Ki67 and potential markers of sensitivity to cetuximab and imatinib. Simultaneously with the first research biopsy, research-related blood samples will be collected to assess circulating tumor cells through the course of the trial. Subjects will receive two doses of cetuximab as follows: a loading dose of 400 mg/m2 on Day 1 and 250 mg/m2 on Day 8. In addition, they will take 400 mg of imatinib orally daily for a period ranging from a minimum of 8 days to a maximum of 14 days before undergoing definitive surgery or definitive radiation/chemoradiation. Following the combined treatment with imatinib and cetuximab, subjects will undergo a second research blood draw and a research biopsy. The administration of imatinib will be discontinued 1-3 days prior to the second research biopsy. For patients undergoing surgical resection, this second research biopsy will be obtained during the surgical procedure. Patients will return for follow-up visits at 1, 3, and 12 months after completing definitive therapy to assess toxicities, monitor adverse events, and collect blood samples. Enrollment in the study is ongoing. NCT05816785 Results TBD Conclusion TBD
oncology,radiology, nuclear medicine & medical imaging